ABSTRACT 5-Fluoro-2'-deoxycytidine (FdCyd) is a potent inhibitor ofgrowth of tissue culture cells. The major cytotoxic event appears to be inhibition of thymidylate synthetase as evidenced by reversal of the cytotoxicity with thymidine but not deoxycytidine and by the effect ofFdCyd on nucleotide pools, which is characteristic of specific inhibition of this enzyme. The metabolism of FdCyd was established by using a method in which its cytotoxicity was compared in several S49 mutant cell lines having defined single or double deficiencies ofenzymes involved in nucleoside and nucleotide metabolism. Our results indicate that FdCyd is metabolized to 5-fluoro-2'-deoxyuridylate, a potent inhibitor of thymidylate synthetase by two pathways: (i) sequential reactions catalyzed by deoxycytidine kinase and deoxycytidylate deaminase and (ii) sequential reactions catalyzed by cytidine deaminase and thymidine kinase. We have shown that metabolism of FdCyd can be directed through the former pathway by inhibition of cytidine deaminase with tetrahydrouridine. Since cytidine deaminase appears to be responsible for catabolism of FdCyd in animals, our results suggest that the antineoplastic effects of FdCyd should be examined in combination with inhibitors of cytidine deaminase.
5-Fluorodeoxycytidine (FdCyd) is a potent cytotoxic agent in tissue culture systems (1) (2) (3) . Because the effects of FdCyd are so similar to those of5-fluorodeoxyuridine (FdUrd) and are reversed by thymidine, it has been postulated that its mechanism ofaction involves deamination to FdUrd by cytidine deaminase, conversion to 5-fluorouridylic acid (FdUMP) by thymidine kinase, and subsequent inhibition of dTMP synthetase (4, 5) . FdCyd has also shown activity as an antineoplastic agent in a number of experimental animal tumor models (6) . However, since the spectrum ofactivity and in vivo efficacy ofFdCyd was, with few exceptions, similar to that ofFdUrd and 5-fluorouracil (FUra), studies of its mechanism of action and antineoplastic effects have been largely abandoned.
Our interest in FdCyd was stimulated by reports suggesting that the proposed mechanism of action of FdCyd might be incorrect or, at least, incomplete. First, FdCyd is a potent cytotoxic agent toward FdUrd-resistant sublines of P815Y (7) and L5178Y (3) that lack thymidine kinase. Second, the toxicity of FdCyd in mice was increased by administration of tetrahydrouridine (H4Urd), a potent inhibitor of cytidine deaminase (8) ; if conversion to FdUrd were necessary for activation of FdCyd, the opposite effect would have occurred.
In this paper, we describe experiments to elucidate the mechanism ofFdCyd metabolism and action in S49 mouse lymphoma cells. The approach used relies mainly on use of the mutant cell lines deficient in one or more of the enzymes involved in nucleoside and nucleotide metabolism that have been developed by Martin and co-workers (9) (10) (11) . By simply testing the effects ofa nucleoside analog on such mutants, it is possible to determine which enzyme activities are necessary for conversion to the cytotoxic metabolite. As (12) as well as the mutant strains used in this study. The deoxycytidine kinase-deficient (dCK-), thymidine kinase-deficient (TK-), and dCMP deaminase-deficient (dCMPD-) cell lines are described elsewhere (9) (10) (11) . Starting with the dCMPD-and the dCK-cells, dCMPD-/TK-and dCK-/TK-double mutants were selected for resistance to 5-bromodeoxyuridine as described for the TKline (10) .
Lack of thymidine kinase activity in the latter two cell lines was confirmed by resistance ofthe cells to 1 uM FdUrd and by the inability of a cell-free sonicate to phosphorylate thymidine in the following assay. Approximately 108 cells were sonicated for 20 sec in 0.3 ml ofbuffer (10 mM mercaptoethanol/20 mM sodium phosphate, pH 7.4) using a Biosonik sonicator set at pI = 40. Cellular debris was removed by centrifugation for 4 cultures for each growth condition were counted in a Coulter model ZBI cell counter at 24, 48, and 72 hr. The percentage of control growth is 100 times the slope of the plot of the logarithm ofthe number of cells versus time, divided by the slope of the plot for the untreated control culture (13) . The 50% growth-inhibitory concentration (EC50) was estimated from plots of the percentage of control growth as a function of the logarithm of the inhibitor concentration. All additions were made at the beginning of the experiments.
The ribonucleoside and deoxyribonucleoside triphosphate content of cell extracts was assessed by HPLC techniques as reported (14, 15) In principle, the cytotoxic effects ofFdCyd would result from one or more of three possible metabolites: FUra, FdUMP, or FdCTP ( Fig. 1 ). Since FdCyd (EC50 2 nM) is some 103-fold more cytotoxic toward tissue culture cells than is FUra, we may rule out the possibility that the latter is responsible for the effects of FdCyd in vitro. However, as discussed below, FUra is probably the catabolite of FdCyd that is responsible for its in vivo activity. Conversion of FdCyd to FdUMP would result in potent inhibition of dTMP synthetase whereas conversion to FdCTP might be expected to result in effects on DNA synthesis in a manner similar to that of 1-f3-D-arabinofuranosylcytosine 5'-triphosphate (araCTP) (16) and 1-f-D-arabinofuranosyl-5-fluorocytosine 5'-triphosphate (17) . Distinguishing between these possible modes of action is most easily accomplished by demonstrating the reversal of cytotoxicity by agents that circumvent or abolish the specific blockade. That is, the effect of inhibition of dTMP synthetase can be effectively reversed by thymidine but only poorly reversed by deoxycytidine. The rationale for these effects is that thymidine provides a source of thymidine nucleotides and thus circumvents the block whereas deoxycytidine must be converted to dUMP, which must compete with the inhibitor for dTMP synthetase; in contrast, the effects ofaraC and 1-,B D-arabinofuranosyl-5-fluorocytosine are reversed by deoxycytidine but not thymidine (17) . Cheong et aL (2) itory effects ofFdCyd (2), indicating that the toxic effects ofthis drug toward this cell line were due to inhibition of dTMP synthetase. Similarly, we have shown that, when S-49 cells are treated with a high concentration (10 times the EC50) ofFdCyd, coadministration of 3 AuM thymidine permitted 67% of control growth, whereas deoxycytidine was much less effective, with only 40% of control growth observed at 50 /iM ( Fig. 2A) . Parallel studies on reversal of the effect of FdUrd-a specific inhibitor of dTMP synthetase in S-49 cells (18)-yielded a nearly identical pattern; at 10 times the EC50 of FdUrd, 1 .tM thymidine afforded 51% reversal of inhibition whereas only a 17% reversal occurred at 50 ,M deoxycytidine (Fig. 2B) . The pattern ofreversal ofaraC cytotoxicity ofS-49 cells by these nucleosides is clearly distinct from those described for FdCyd and FdUrd: at 10 times the EC50 of araC, 30 ,uM thymidine had no effect on growth inhibition whereas 30 uM deoxycytidine restored growth to 55% of control (Fig. 2C ).
We have found that specific inhibition of dTMP synthetase in logarithmically growing cells produces a characteristic, and perhaps unique, pattern of changes in NTP pool sizes (unpublished results). A primary effect ofinhibition ofdTMP synthesis in tissue culture cells results in a decline in dTTP levels that, through direct and indirect effects on ribonucleotide reductase, causes changes in the levels of other dNTPs that are in good agreement with reported models of allosteric effects on this enzyme (19, 20) . A decrease in dTTP is accompanied by a decline in dGTP levels because the former is an allosteric activator of GDP reduction. There is often a smaller increase in dATP that presumably results from the release ofallosteric inhibition of ADP reduction by dTTP even in the face of decreased ADP reduction resulting from depletion of the positive activator, dGTP. Ifthe blockade ofdTMP synthetase persists, a decrease in the allosteric inhibition of CDP reduction by dTTP can also be manifested by increases in dCTP. However, we usually do not observe increased dCTP until after the aforementioned changes have occurred. Changes in pool sizes ofribonucleotides have been found to be insignificant if the blockade of dTMP synthetase is truly specific. This pattern of characteristic changes that results from intracellular depletion of dTMP and dTTP is illustrated in Table 1 , which shows the deoxyribonucleoside triphosphate levels in cells treated with FdUrd for 3 hr, which under the conditions used causes specific inhibition of dTMP synthetase (18) . Note that, as described above, there is a significant depletion of dTTP and dGTP, and a slight increase in dATP; longer periods of incubation result in an increase in dCTP (not shown). Ribonucleotide pools are slightly increased after 3 hr of incubation ( Table 2) . Treatment of S-49 cells with araC produced an entirely different profile of intracellular dNTP pool sizes: there is a slight depletion of dCTP, a moderate increase in dTTP, and very large (ca. 3-fold) increases in both dGTP and dATP. As with inhibitors of dTMP synthetase, araC did not deplete the pool sizes of NTPs. When S-49 cells were treated with FdCyd, there were no significant changes observed in the NTP pool sizes; however, there were large decreases in dTTP and dGTP and an increase in dATP-characteristic ofspecific inhibition ofdTMP synthetase as is observed with FdUrd.
The above results thus show that the cytotoxic effect of FdCyd on S-49 cells is primarily, probably exclusively, a result of dTMP synthetase inhibition. Nucleotides of FdCyd (e.g., FdCMP) are not themselves potent inhibitors of this enzyme (21) , and the most logical candidate for the cytotoxic metabolite is FdUMP. As shown in Fig. 1 , there are two major metabolic routes by which FdCyd can be converted to FdUMP. The first path (path A) involves cytidine deaminase-catalyzed deamination to FdUrd and its subsequent phosphorylation to FdUMP by deoxycytidine kinase. Path B involves initialphosphorylation of FdCyd by deoxycytidine kinase to form FdCMP followed by Aliquots of the neutralized trichloroacetic acid extracts used in Table 1 were analyzed for NTP pools by HPLC (15 (4, 18, 24) . Which of these effects is primarily responsible for the action of FUra remains controversial. In spite ofthe controversy, it is clear that, in tissue culture systems, FdUrd and FUra may behave as quite different agents. In vivo FdUrd and FUra show the same spectrum of activity at approximately equimolar concentrations. FdUrd is an excellent substrate for both thymidine and uridine phosphorylases, and it is probable that in vivo FdUrd-is converted to FUra more rapidly than it enters target cells to be directly converted to FdUMP. This has been recognized by workers attempting to develop agentsthat might block this catabolic process and thus reveal the direct effect FdUrd may have on dTMP synthesis without the RNA incorporation so prevalent with FUra. In animal tumor models, FdCyd also shows a similar spectrum of activity and potency as does FUra, which is in marked contrast to their differences in tissue culture cells. Thus, it is reasonable to surmise that FdCyd also serves as a source of FUra in vivo. Since mammalian cells do not possess enzymes that cleave the glycosidic bond ofcytosine nucleosides (25) , the metabolism must involve deamination by cytidine deaminase to give FdUrd followed by phosphorolysis to FUra. If cytidine deaminase could be blocked, the catabolism of FdCyd would be prevented and its metabolism would be directed through path B, involving phosphorylation to FdCMP and subsequent deamination by dCMP deaminase to the dTMP synthetase inhibitor, FdUMP. H4Urd is an effective nontoxic inhibitor ofcytidine deaminase both in vitro and in vivo (26) . We believe that an in vivo trial of FdCyd in combination of an inhibitor of cytidine deaminase is warranted. Based on the discussion above, we expect that the antitumor effect of this regimen would be quite different than that observed for FdCyd alone. Indeed, H4Urd has been shown to significantly increase the toxicity of FdCyd in mice (8) . This combination might be particularly useful against neoplasms such as acute nonlymphocytic leukemia that are responsive to araC (27) . Further, since the mechanisms-of action of araC and FdCyd are so different but both drugs are targeted toward cells rich in deoxycytidine kinase, they could act synergistically providing that H4Urd was used to prevent catabolism.
